Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Free Cash Flow (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Free Cash Flow for 5 consecutive years, with $75.1 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow rose 57.09% to $75.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $197.8 million through Dec 2025, up 72.11% year-over-year, with the annual reading at $197.8 million for FY2025, 72.11% up from the prior year.
  • Free Cash Flow hit $75.1 million in Q4 2025 for Krystal Biotech, up from $47.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $75.1 million in Q4 2025 to a low of -$66.0 million in Q4 2021.
  • Historically, Free Cash Flow has averaged -$982600.0 across 5 years, with a median of -$10.1 million in 2021.
  • Biggest five-year swings in Free Cash Flow: tumbled 263.38% in 2022 and later skyrocketed 968.43% in 2025.
  • Year by year, Free Cash Flow stood at -$66.0 million in 2021, then soared by 115.91% to $10.5 million in 2022, then crashed by 175.46% to -$7.9 million in 2023, then skyrocketed by 702.71% to $47.8 million in 2024, then skyrocketed by 57.09% to $75.1 million in 2025.
  • Business Quant data shows Free Cash Flow for KRYS at $75.1 million in Q4 2025, $47.1 million in Q3 2025, and $46.0 million in Q2 2025.